Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 3

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Thoracic 3Gastrointestinal 3Gynecologic 2Breast 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Melanoma 1Lung Neoplasms 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × entinostat × Thoracic × Clear all
NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Syndax Pharmaceuticals

Phase 1/2 Completed
191 enrolled 26 charts
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00602030 2022-08-22

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Syndax Pharmaceuticals

Phase 1/2 Completed
141 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00387465 2019-05-09

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
94 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡